JNJ-38877618

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H12F2N6
Molecular Weight	374.3463
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

FC(F)(C1=NN=C2C=CC(=NN12)C3=CC=NC=C3)C4=CC5=C(C=C4)N=CC=C5

InChI

InChIKey=KOAWAWHSMVKCON-UHFFFAOYSA-N

InChI=1S/C20H12F2N6/c21-20(22,15-3-4-16-14(12-15)2-1-9-24-16)19-26-25-18-6-5-17(27-28(18)19)13-7-10-23-11-8-13/h1-12H

HIDE SMILES / InChI

Molecular Formula	C20H12F2N6
Molecular Weight	374.3463
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 11:54:47 GMT 2023` Edited by `admin` on `Sat Dec 16 11:54:47 GMT 2023`
Record UNII	E0B2IZB5H5
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

JNJ-38877618

Code

English

OMO-1

Code

English

OMO1

Code

English

6-(DIFLUORO-(6-(4-PYRIDYL)-(1,2,4)TRIAZOLO(4,3-B)PYRIDAZIN-3-YL)METHYL)QUINOLINE

Systematic Name

English

QUINOLINE, 6-(DIFLUORO(6-(4-PYRIDINYL)-1,2,4-TRIAZOLO(4,3-B)PYRIDAZIN-3-YL)METHYL)-

Systematic Name

English

OMO 1 [WHO-DD]

Common Name

English

JNJ38877618

Code

English

Code System Code Type Description

CAS

943540-74-7

Created by admin on Sat Dec 16 11:54:47 GMT 2023 , Edited by admin on Sat Dec 16 11:54:47 GMT 2023

PRIMARY

FDA UNII

E0B2IZB5H5

Created by admin on Sat Dec 16 11:54:47 GMT 2023 , Edited by admin on Sat Dec 16 11:54:47 GMT 2023

PRIMARY

PUBCHEM

57654476

Created by admin on Sat Dec 16 11:54:47 GMT 2023 , Edited by admin on Sat Dec 16 11:54:47 GMT 2023

PRIMARY

SMS_ID

300000042483

Created by admin on Sat Dec 16 11:54:47 GMT 2023 , Edited by admin on Sat Dec 16 11:54:47 GMT 2023

PRIMARY

Related Record Type Details


					E0B2IZB5H5

JNJ-38877618

ACTIVE MOIETY

Comments:

Originator: Janssen-Cilag; Mechanism of Action: Proto oncogene protein c met inhibitor; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Highest Development Phase: Phase I for Cancer; Most Recent Event: 15 Oct 2013 Janssen-Cilag plans a phase I trial for Healthy volunteers in the UK (NCT01964872)

Amount: